Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: An analytical point of view

Current Drug Metabolism

Volumn 11, Issue 9, 2010, Pages 815-829

  Mandrioli, Roberto ^a   Mercolini, Laura ^a   Raggi, Maria Augusta ^a  

^a Faculty of Pharmacy   (Italy)

Author keywords

Analytical methods; Anxiolytics; Cytochrome P450; Non benzodiazepines; Sedative hypnotics

Indexed keywords

ALCHERA; ALPRAZOLAM; ANXIOLYTIC AGENT; BARBITAL; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BROMISOVAL; BUSPIRONE; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAMIXAN; DIAZEPAM; FLUNITRAZEPAM; FLUVOXAMINE; HYPNOTIC AGENT; IMOZOP; IMREST; IVEDAL; LIMOVAN; LIORAN; LORAZEPAM; MIDAZOLAM; NASEN; NOCTURNO; NYTAMEL; OXAZEPAM; PHENYTOIN; RAMELTEON; RELAXON; RHOVANE; SANVAL; SOMIDEM; SUCEDA; TANDOSPIRONE; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLA; ZALEPLON; ZDORM; ZILEZE; ZIMOCLONE; ZOLDEM; ZOLNOD; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOLPIHEXAL; ZOPICLONE; ZOPIMED; ZOPITAN; ZOPIVANE; ZORCLONE;

AREA UNDER THE CURVE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; DRUG TRANSFORMATION; FATIGUE; FOOD; HUMAN; IN VIVO STUDY; INSOMNIA; NAUSEA; RESPIRATION DEPRESSION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 79851481147     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010794328887     Document Type: Review

References (132)

1. th World Congress of Psychiatry, Mexico City, Mexico, November 28-30, 1971; de la Fuente, R.; Weisman, M., Eds.; Elsevier: New York, USA, 1973, pp. 87-88.
2. Ohayon, M. M.; Lader, M. H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J. Clin. Psychiat., 2002, 63(9), 817-825.
3. Alonso, J; Angermeyer, M. C.; Bernert, S.; Bruffaerts, R.; Brugha, T. S.; Bryson, H.; de Girolamo, G.; Graaf, R.; Demyttenaere, K.; Gasquet, I.; Haro, J. M.; Katz, S. J.; Kessler, R. C.; Kovess, V.; Lépine, J. P.; Ormel, J.; Polidori, G.; Russo, L. J.; Vilagut, G.; Almansa, J.; Arbabzadeh-Bouchez, S.; Autonell, J.; Bernal, M.; Buist-Bouwman, M. A.; Codony, M.; Domingo-Salvany, A.; Ferrer, M.; Joo, S. S.; Martínez-Alonso, M.; Matschinger, H.; Mazzi, F.; Morgan, Z.; Morosini, P.; Palacín, C.; Romera, B.; Taub, N.; Vollebergh, W. A.; ESEMeD/MHEDEA 2000 Investigators. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand., 2004, 109 (Suppl. 420), 55-64.
4. Grinshpoon, A.; Marom, E.; Weizman, A.; Ponizovsky, A. M. Psychotropic drug use in israel: results from the national health survey. Prim. Care Companion J. Clin. Psychiat., 2007, 9(5), 356-363. (Pubitemid 350126137)
5. Johns, M. W. Sleep and hypnotic drugs. Drugs, 1975, 9(6), 448-478.
6. th ed.); Sadock, V. A.; Sadock, B. J.; Kaplan, H. I., Eds; Lippincott Williams & Wilkins: Philadelphia, 2001, pp. 2317-2123.
7. Cole, J. O.; Chiarello, R. J. The benzodiazepines as drugs of abuse. J. Psychiatr. Res., 1990, 24 (Suppl 2), 135-144. (Pubitemid 20374706)
8. U. S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section, Springfield (VA). Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals. November 2009. http://www.deadiversion. usdoj.gov/21cfr/cfr/1308/1308-14.htm (Accessed October 13, 2010).
9. European Monitoring Centre for Drugs and Drug Addiction, European Legal Database on Drugs, Substances and classifications table, Lisbon. November 2008. http://eldd.emcdda.europa.eu/attachements.cfm/att-65482-EN- Substances%20and%20classifications%20Nov08.xls (Accessed October 13, 2010).
10. Siriwardena, A. N.; Qureshi, M. Z.; Dyas, J. V., Middleton, H.; Orner, R. Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. Br. J. Gen. Pract., 2008, 58(551), 417-422. (Pubitemid 351780899)
11. Mandrioli, R.; Mercolini, L.; Raggi, M. A. Benzodiazepine metabolism: an analytical perspective. Curr. Drug Metab., 2008, 9(8), 827-844.
12. Owen, R. T. Novel zolpidem formulations. Drug. Today, 2009, 45(5), 395-400.
13. Priest, R. G. Pharmacological management of insomnia: the current approach. Ther. Express, 1997, 5, 1-4.
14. Depoortere, H.; Zivkovic, B.; Lloyd, KG.; Sanger, D. J.; Perrault, G.; Langer, S. Z.; Bartholini, G. Zolpidem, a novel nonbenzo-diazepine hypnotic. I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther., 1986, 237(2), 649-658. (Pubitemid 16092830)
15. Rosenberg, R. P. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann. Clin. Psychiat., 2006, 18(1), 49-56.
16. Lobo, B. L.; Greene, W. L. Zolpidem: Distinct from triazolam? Ann. Pharmacother., 1997, 31(5), 625-632. (Pubitemid 27203964)
17. Barkin, R. L. Zolpidem extended-release: A single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am. J. Ther., 2007, 14(3), 299-305. (Pubitemid 46791569)
18. Chouinard, G.; Lefko-Singh, K.; Teboul, E. Metabolism of anxiolytics and hypnotics: Benzodiazepines, buspirone, zoplicone, and zolpidem. Cell. Mol. Neurobiol., 1999, 19(4), 533-552. (Pubitemid 29283828)
19. rd International ISSX Meeting, Amsterdam, The Netherlands, June 24-28, 1991; Mulder, G.; Vermeulen, N. P. E., Eds.; Amsterdam, The Netherlands, 1991; p. 153.
20. Thénot, J. P.; Hermann, P.; Durand, A.; Burke, J. T.; Allen, J.; Garrigou, D.; Vajta, S.; Albin, H.; Thibault, J. J.; Olive, O.; Warrington, S. J. In: Imidazopyridines in sleep disorders; Sauvanet, J. P.; Langer, S. Z.; Morselli, P. L., Eds.; Raven Press: New York, 1988, pp. 139-153.
21. Pichard, L.; Gillet, G.; Bonfils, C.; Domergue, J.; Thénot, J. P.; Maurel, P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab. Dispos., 1995, 23(11), 1253-1262.
22. von Moltke, L. L.; Greenblatt, D. J.; Granda, B. W.; Xiang Duan, S.; Grassi, J. M.; Venkatakrishnan, K.; Harmatz, J. S.; Shader, R. I. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br. J. Clin. Pharmacol., 1999, 48(1), 89-97. (Pubitemid 29296668)
23. Olubodun, J. O.; Ochs, H. R.; Von Moltke, L. L.; Roubenoff, R.; Hesse, L. M.; Harmatz, J. S.; Shader, R. I.; Greenblatt, D. J. Pharmacokinetic properties of zolpidem in elderly and young adults: Possible modulation by testosterone in men. Br. J. Clin. Pharmacol., 2003, 56(3), 297-304. (Pubitemid 37069221)
24. Olubodun, J. O.; Ochs, H. R.; Trüten, V.; Klein, A.; Von Moltke, L. L.; Harmatz, J. S.; Shader, R. I.; Greenblatt, D. J. Zolpidem pharmacokinetic properties in young females: Influence of smoking and oral contraceptive use. J. Clin. Pharmacol., 2002, 42(10), 1142-1146.
25. Hesse, L. M.; Von Moltke, L. L.; Greenblatt, D. J.; Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs, 2003, 17(7), 513-532. (Pubitemid 36693705)
26. Polasek, T. M.; Sadagopal, J. S.; Elliot, D. J.; Miners, J. O. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur. J. Clin. Pharmacol., 2010, 66(3), 275-283.
27. Bomsien, S.; Skopp, G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur. J. Clin. Pharmacol., 2007, 63(9), 821-827. (Pubitemid 47237898)
28. Bomsien, S.; Aderjan, R.; Mattern, R.; Skopp, G. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur. J. Clin. Pharmacol., 2006, 62(8), 639-643. (Pubitemid 44127993)
29. Greenblatt, D. J.; Von Moltke, L. L.; Harmatz, J. S.; Mertzanis, P.; Graf, J. A.; Durol, A. L. B.; Counihan, M.; Roth-Schechter, B.; Shader, R. I. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin. Pharmacol. Ther., 1998, 64(6), 661-671. (Pubitemid 29011386)
30. Villikka, K.; Kivistö, K. T.; Luurila, H.; Neuvonen, P. J. Rifampin reduces plasma concentrations and effects of zolpidem. Clin. Pharmacol. Ther., 1997, 62(6), 629-634. (Pubitemid 28068066)
31. Myslobodsky, M. The paradox of caffeine-zolpidem interaction: a network analysis. Curr. Drug Targets, 2009, 10(10), 1009-1020.
32. Durol, A. L. B.; Greenblatt, D. J. Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies. J. Anal. Toxicol., 1997, 21, 388-392. (Pubitemid 27391402)
33. Noguchi, H.; Kitazumi, K.; Mori, M.; Shiba, T. Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. Eur. J. Pharmacol., 2002, 434 (1-2), 21-28. (Pubitemid 34033741)
34. U. S. Food & Drug Administration. FDA Approved Drug Products: Zaleplon. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search. Overview & DrugName=ZALEPLON (Accessed October 1, 2010.)
35. Patat, A.; Paty, I.; Hindmarch, I. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum. Psychopharmacol., 2001, 16(5), 369-392. (Pubitemid 32747103)
36. King Pharmaceuticals. Sonata medication guide, November 2009. http://66.29.199.249/products/product-document.cfm?brand-name= Sonata&product-specific-name=CIV&document-type-code=PI (Accessed October 1, 2010).
37. Rosen, A. S.; Fournié, P.; Darwish, M.; Danjou, P.; Troy, S. M.; Zaleplon pharmacokinetics and absolute bioavailability. Biopharm. Drug Dispos., 1999, 20(3), 171-175. (Pubitemid 29137676)
38. Drover, D. R. Comparative pharmacokinetics and pharmaco-dynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokin., 2004, 43(4), 227-238. (Pubitemid 38429303)
39. Noguchi, H.; Kitazumi, K.; Mori, M.; Shiba, T. Effect of zaleplon on learning and memory in rats. N. S. Arch. Pharmacol., 2002, 366(2), 183-188. (Pubitemid 34762279)
40. Barbera, J.; Shaprio, C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Safety, 2005, 28(4), 301-318. (Pubitemid 40545766)
41. th Ed., Merck & Co., Whitehouse Station (NJ), January 2010. http://www.merck.com/mmpe/ lexicomp/zaleplon.html (Accessed October 13, 2010).
42. Lake, B. G.; Ball, S. E.; Kao, J.; Renwick, A. B.; Price, R. J.; Scatina, J. A. Metabolism of zaleplon by human liver: Evidence for involvement of aldehyde oxidase. Xenobiotica, 2002, 32(10), 835-847. (Pubitemid 35155519)
43. Renwick, A. B.; Mistry, H.; Ball, S. E.; Walters, D. G.; Kao, J.; Lake, B. G. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 1998, 28(4), 337-348. (Pubitemid 28207039)
44. Horstkötter, C., Schepmann, D., Blaschke, G. Separation and identification of zaleplon metabolites in human urine using capillary electrophoresis with laser-induced fluorescence detection and liquid chromatography-mass spectrometry. J. Chromatogr. A, 2003, 1014 (1-2), 71-81. (Pubitemid 37311159)
45. Heydorn, W. E. Zaleplon - A review of a novel sedative hypnotic used in the treatment of insomnia. Expert Opin. Inv. Drug, 2000, 9(4), 841-858. (Pubitemid 30175650)
46. Renwick, A. B.; Ball, S. E.; Tredger, J. M.; Price, R. J.; Walters, D. G.; Kao, J.; Scatina, J. A.; Lake, B. G. Inhibition of zaleplon metabolism by cimetidine in the human liver: In vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica, 2002, 32(10), 849-862. (Pubitemid 35155520)
47. Obach, R. S. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab. Dispos., 2004, 32(1), 89-97. (Pubitemid 38112540)
48. Beer, B.; Ieni, J. R.; Wu, W. H.; Clody, D.; Amorusi, P.; Rose, J.; Mant, T.; Gaudreault, J.; Cato, A.; Stern, W. A placebo-controlled evaluation of single, escalating doses of zaleplon, a nonbenzodiazepine hypnotic. J. Clin. Pharmacol., 1994, 34, 335-344. (Pubitemid 24138965)
49. Kawashima, K.; Hosoi, K.; Naruke, T.; Shiba, T.; Kitamura, M.; Watabe, T. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab. Dispos., 1999, 27, 422-428. (Pubitemid 29114253)
50. Goa, K. L.; Heel, R. C. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs, 1986, 32(1), 48-65. (Pubitemid 16093297)
51. Stutzmann, J. M.; Delahaye, C.; Allain, H. Zopiclone: Data of experimental pharmacology and therapeutic trials. Therapie, 1993, 48(1), 33-42. (Pubitemid 23044435)
52. Holbrook, A. M.; Crowther, R.; Lotter, A.; Cheng, C; King, D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can. Med. Assoc. J., 2000, 162(2), 225-233. (Pubitemid 30073249)
53. U. S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section, Springfield (VA). Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals. November 2009. http://www.deadiversion. usdoj.gov/schedules/orangebook/ orangebook.pdf (Accessed October 1, 2010).
54. Fernandez, C; Martin, C; Gimenez, F.; Farinotti, R. Clinical pharmacokinetics of zopiclone. Clin. Pharmacokin., 1995, 29(6), 431-441. (Pubitemid 26004180)
55. Gaillot, J.; Heusse, D.; Hougton, G. W. Pharmacokinetics and metabolism of zopiclone. Pharmacology, 1983, 27 (Suppl. 2), 76-91. (Pubitemid 14181629)
56. Fernandez, C; Alet, P.; Davrinche, C; Adrien, J.; Thuillier, A.; Farinotti, R.; Gimenez, F. Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J. Pharm. Pharmacol, 2002, 54(3), 335-340. (Pubitemid 34232334)
57. Blaschke, G.; Hempel, G.; Müller, W. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality, 1993, 5(6), 419-421. (Pubitemid 23293270)
58. Fernandez, C; Maradeix, V.; Gimenez, F.; Thuillier, A.; Farinotti, R. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab. Dispos., 1993, 21(6), 1125-1128. (Pubitemid 23348352)
59. Hair, P. I.; McCormack, P. L.; Curran, M. P.; Eszopiclone: A review of its use in the treatment of insomnia. Drugs, 2008, 68(10), 1415-1434. (Pubitemid 351913436)
60. European Medicines Agency, London. Human Medicines: Withdrawn applications, Lunivia, 2009. http://www.ema.europa.eu/docs/en-GB/document- library/Other/2010/01/WC500061613.pdf (Accessed October 1, 2010).
61. Melton, S. T.; Wood, J. M.; Kirkwood, C. K. Eszopiclone for insomnia. Ann. Pharmacother., 2005, 39(10), 1659-1666. (Pubitemid 41393125)
62. Halas, C. J. Cost-effectiveness of eszopiclone for the treatment of chronic insomnia. Expert Rev. Pharmacoecon. Outcomes Res., 2007, 7(1), 9-17.
63. Koppenhoefer, B.; Epperlein, U.; Christian, B.; Lin, B.; Ji, Y.; Chen, Y. Separation of enatiomers of drugs by capillary electrophoresis III. p-cyclodextrin as chiral solvating agent. J. Chromatogr. A, 1996, 735 (1-2), 333-343.
64. Fernandez, C; Baune, B.; Gimenez, F.; Thuillier, A.; Farinotti, R. Determination of zopiclone enantiomers in plasma by liquid chromatography using a chiral cellulose carbamate column. J. Chromatogr. B, 1991, 572, 195-202.
65. Fernandez, C; Gimenez, F.; Baune, B.; Maradeix, V.; Thuillier, A.; Farinotti, R. Determination of the enantiomers of zopiclone and its two chiral metabolites in urine using an automated coupled achiral-chiral chromatographic system. J. Chromatogr. B, 1993, 617(2), 271-278. (Pubitemid 23248374)
66. Maier, G.; Hsu, R.; Broward, M.; Russell, T.; Levasseur, L. Evaluation of eszopiclone permeability using the Caco-2 in vitro model. Pharm. Sci., 2003, 5, 2127.
67. Leese, P.; Maier, G.; Vaickus, L. Eszopiclone: pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects. Sleep, 2002, 25, 45.
68. Maier, G.; Koch, P.; Caron, J.; Amato, D.; Britto, M.; Russell, T.; Levasseur, L. Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing. Pharm. Sci., 2003, 5, 1325.
69. Nguyen, N. N.; Yu, S. S.; Song, J. C.; Quercia, R. A.; Coleman, C. I. Ramelteon: A novel melatonin receptor agonist for the treatment of insomnia. Formulary, 2005, 40(5), 146-155. (Pubitemid 40733437)
70. Borja, N. L.; Daniel, K. L. Ramelteon for the treatment of insomnia. Clin. Ther., 2006, 28(10), 1540-1555. (Pubitemid 44841983)
71. McGechan, A.; Wellington, K. Ramelteon. CNS Drugs, 2005, 19(12), 1057-1065. (Pubitemid 41775995)
72. Anonymous, Ramelteon: new drug. Insomnia: No role for risky placebos. Prescrire Int., 2008, 17(97), 183-186.
73. Neubauer, D. N. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatric Dis. Treat., 2008, 4 1 A), 69-79.
74. Sateia, M. J.; Kirby-Long, P.; Taylor, J. L. Efficacy and clinical safety of ramelteon: An evidence-based review. Sleep Med. Rev., 2008, 12(4), 319-332. (Pubitemid 351899319)
75. Karim, A.; Tolbert, D.; Zhao, Z. Single and multiple dose pharmacokinetic evaluation of ramelteon (TAK-375) in subjects with and without hepatic impairment. J. Clin. Pharmacol., 2004, 44, 1210.
76. Amakye, D. D.; Hibberd, M., Stevenson, S. J. A phase I study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Sleep, 2004, 27, 54.
77. Scott Obach, R.; Ryder, T. F. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab. Dispos., 2010, 38(8), 1381-1391.
78. Karim, A.; Tolbert, D.; Cao, C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J. Clin. Pharmacol., 2006, 46, 140-148. (Pubitemid 43146444)
79. Stevenson, S.; Cornelissen, K.; Clarke, E.; Hibberd, M. Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375). Clin. Pharmacol. Ther., 2004, 75, 22.
80. Greenblatt, D. J.; Harmatz, J. S.; Karim, A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT 1 and MT2. J. Clin. Pharmacol., 2007, 47, 485-496. (Pubitemid 46465960)
81. Reynoldson, J. N.; Elliott, E. Sr.; Nelson, L. A. Ramelteon: A Novel Approach in the Treatment of Insomnia. Ann. Pharmacother., 2008, 42, 1262-1271.
82. U. S. Food & Drug Administration. FDA Approved Drug Products: Rozerem. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 021782s008s009s010lbl.pdf (Accessed October 1, 2010).
83. Karim, A.; Tolbert, D.; Cao, C.; Zhao, Z.; Sainati, S. M. Effects of fluconazole and ketoconazole on the pharmacokinetics of ramelteon (TAK-375) in normal healthy male and female subjects. Sleep, 2004, 27, 53-54.
84. Sainati, S. M.; Karim, A.; Tolbert, D.; Cao, C. Effects of multiple doses of fluoxetine on the systemic exposure of a single dose of ramelteon (TAK-375) in healthy adults. Sleep, 2004, 27, 48.
85. Tolbert, D.; Karim, A.; Johnson, J. Two-period crossover study to assess the drug interaction between ramelteon (TAK-375) and theophylline in healthy adults. Sleep, 2004, 27, 48-48.
86. Blier, P.; Bergeron, R.; De Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology, 1997, 16(5), 333.
87. Eison, M. S.; Eison, A. S. Buspirone as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms. Drug Dev. Res., 1984, 4(1), 109-119. (Pubitemid 14173352)
88. Rickles, K. Buspirone in clinical practice. J. Clin. Psychiatry, 1990, 51 (suppl 9), 51-54.
89. th ed.; American Psychiatric Publishing: Arlington, 2010.
90. Mahmood, I.; Sahajwalla, C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin. Pharmacokin., 1999, 36(4), 277-287. (Pubitemid 29201736)
91. Zhu, M.; Zhao, W.; Jimenez, H.; Zhang, D.; Yeola, S.: Dai, R.; Vachharajani, N.; Mitroka, J. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos., 2005, 33(4), 500-507. (Pubitemid 40393192)
92. Kivistö, K. T.; Lamberg, T. S.; Kantola, T.; Neuvonen, P. J. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther., 1997, 62(3), 348-354. (Pubitemid 27417801)
93. Lilja, J. J.; Kivistö, K. T.; Backman, J. T.; Lamberg, T. S.; Neuvonen, P. J. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin. Pharmacol. Ther., 1998, 64(6), 655-660. (Pubitemid 29011385)
94. Blier, P.; Curet, O.; Chaput, Y.; De Montigny, C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology, 1991, 30(7), 691-701.
95. Zuideveld, K. P.; Rusic-Pavletic, J.; Maas, H. J.; Peletier, L. A.; Van der Graaf, P. H.; Danhof, M. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J. Pharmacol. Exp. Ther., 2002, 303(3), 1130-1137. (Pubitemid 35424398)
96. Raghavan, N.; Zhang, D.; Zhu, M.; Zeng, J.; Christopher, L. CYP2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab. Dispos., 2005, 33(2), 203-208. (Pubitemid 40227464)
97. Kerns, E. H.; Rourick, R. A.; Volk, K. J.; Lee, M. S. Buspirone metabolite structure profile using a standard liquid chromatographic-mass spectrometric protocol. J. Chromatogr. B, 1997, 698 (1-2), 133-145. (Pubitemid 27412514)
98. Dockens, R. C.; Salazar, D. E.; Fulmor, I. E.; Wehling, M.; Arnold, M. E.; Croop, R. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J. Clin. Pharmacol., 2006, 46(11), 1308-1312. (Pubitemid 44564359)
99. Barbhaiya, R. H.; Shukla, U. A.; Pfeffer, M.; Pittman, K. A.; Shrotriya, R.; Laroudie, C.; Gammans, R. E. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur. J. Clin. Pharmacol., 1994, 46(1), 41-47. (Pubitemid 24067587)
100. Nägele, E., Fandino, A. S. Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast liquid chromatography time-of-flight mass spectrometry. J. Chromatogr. A, 2007, 1156, 196-200. (Pubitemid 46935732)
101. Hamik, A.; Oksenberg, D.; Fischette, C.; Peroutka, S. J. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol. Psychiatr., 1990, 28(2), 99-109. (Pubitemid 20226391)
102. Yamauchi, K.; Yamada, S.; Morita, K.; Maeda, H.; Tanaka, M. Comparative study of short-term anxiolytic potency of alprazolam and tandospirone in psychiatric outpatients with anxiety disorders. Hum. Psychopharmacol., 2001, 16(6), 469-473. (Pubitemid 32895590)
103. Nishitsuji, K.; To, H.; Murakami, Y.; Kodama, K.; Kobayashi, D.; Yamada, T.; Kubo, C.; Mine, K. Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. Clin. Drug Invest., 2004, 24(2), 121-126. (Pubitemid 38316601)
104. Sasa M. A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist tandospirone. J. Clin. Psychopharmacol., 1997, 17(4), 272-277.
105. Barradell, L. B.; Fitton, A. Tandospirone. CNS Drugs, 1996, 5, 147-153. (Pubitemid 26060695)
106. Nishikawa, H.; Inoue, T.; Masui, T.; Izumi, T.; Koyama, T. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog. Neuro-Psychoph., 2007, 31(4), 926-931. (Pubitemid 46660305)
107. Natsui, K.; Mizuno, Y.; Tani, N.; Yabuki, M.; Komuro, S. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes. Eur. J. Drug Metab. Pharmacokin., 2007, 32(4), 233-240. (Pubitemid 351269812)
108. Miller, L. G.; Thompson, M. L.; Byrnes, J. J.; Greenblatt, D. J.; Shemer, A. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J. Clin. Psychopharmacol. 1992, 12, 341-345.
109. Handley, S. L.; McBlane, J. W.; Critchley, M. A. E.; Njung'e, K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res., 1993, 58, 203-210. (Pubitemid 24024059)
110. Tollefson, G. D.; Lancaster, S. P.; Montague-Clouse, J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol. Bull., 1991, 27, 163-170.
111. Nishikawa, H.; Inoue, T.; Masui, T.; Izumi, T.; Koyama, T. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog. Neuro-Psychoph., 2007, 31, 926-931. (Pubitemid 46660305)
112. Nishikawa, H.; Inoue, T.; Masui, T.; Izumi, T.; Nakagawa, S.; Koyama, T. Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: involvement of cytochrome P450 3A4. Psychiat. Clin. Neurosci., 2008, 62(5), 591-596.
113. Nishikawa, H.; Inoue, T.; Izumi, T.; Koyama, T. Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats. Eur. Neuropsychopharmacol., 2007, 17(10), 643-650. (Pubitemid 47268751)
114. Sheehan, D. V.; Sheehan, K. H.; Raj, B. A. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. Psychopharmacol. Bull., 2007, 40(2), 63-81.
115. Podilsky, G.; Berger-Gryllaki, M.; Testa, B.; Buclin, T.; Roulet, M.; Pannatier, A. The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. Eur. J. Clin. Pharmacol., 2009, 65(5), 435-442.
116. Podilsky, G.; Berger-Gryllaki, M.; Testa B.; Pannatier, A. Development and validation of an HPLC method for the simultaneous monitoring of bromazepam and omeprazole. J. Liq. Chromatogr. R. T., 2008, 31, 878-890. (Pubitemid 351281719)
117. Gholipour, T., Rasouli, A., Jabbarzadeh, A., Nezami, B. G., Riazi, K., Sharifzadeh, M., Dehpour, A. R. The interaction of sildenafil with the anticonvulsant effect of diazepam. Eur. J. Pharmacol., 2009, 617 (1-3), 79-83.
118. Naderi, N.; Ahari, F. A.; Shafaghi, B.; Najarkolaei, A. H.; Motamedi, F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J. Neural Transm., 2008, 115(11), 1501-1511.
119. Saari, T. I., Laine, K., Bertilsson, L., Neuvonen, P. J., Olkkola, K. T. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur. J. Clin. Pharmacol., 2007, 63(10), 941-949. (Pubitemid 47387914)
120. Stebler, T.; Guentert, T. W. Determination of diazepam and nordazepam in milk and plasma in the presence of oxazepam and temazepam. J. Chromatogr., 1991, 564(1), 330-337.
121. Matrisciano, F.; Nasca, C.; Molinaro, G.; Riozzi, B.; Scaccianoce, S.; Raggi, M. A.; Mercolini, L.; Biagioni, F.; Mathè, A. A.; Sanna, E.; Maciocco, E.; Pignatelli, M.; Biggio, G.; Nicoletti, F. Enhanced expression of the neuronal K+/Cl-cotransporter, KCC2, in spontaneously depressed Flinders Sensitive Line rats. Brain Res., 2010, 1325(14), 112-120.
122. Mercolini, L.; Mandrioli, R.; Iannello, C.; Matrisciano, F.; Nicoletti, F.; Raggi, M. A. Simultaneous analysis of diazepam and its metabolites in rat plasma and brain tissue by HPLC-UV and SPE. Talanta, 2009, 80(1), 279-285.
123. Wermeling, D. P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics, 2009, 6(2), 352-358.
124. Ivaturi, V. D.; Riss, J. R.; Kriel, R. L.; Siegel, R. A.; Cloyd, J. C. Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Res., 2009, 84 (2-3), 120-126.
125. Chung, J.-Y.; Cho, J.-Y.; Yu, K.-S.; Kim, J.-R.; Lim, K. S.; Sohn, D.-R.; Shin, S.-G.; Jang, I.-J. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther., 2008, 83(4), 595-600. (Pubitemid 351417054)
126. He, X.; Hesse, L. M.; Hazarika, S.; Masse, G.; Harmatz, J. S.; Greenblatt, D. J.; Court, M. H. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br. J. Clin. Pharmacol., 2009, 68(5), 721-730.
127. Smink, B. E.; Hofman, B. J. A.; Dijkhuizen, A.; Lusthof, K. J.; De Gier, J. J.; Egberts, A. C. G.; Uges, D. R. A. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br. J. Clin. Pharmacol., 2008, 66(4), 556-560.
128. Pirnay, S.; Megarbane, B.; Declèves, X.; Risède, P.; Borron, S. W.; Bouchonnet, S.; Perrin, B.; Debray, M.; Milan, N.; Duarte, T.; Ricordel, I.; Baud, F. J. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol. Sci., 2008, 106(1), 64-73.
129. Pirnay, S.; Bouchonnet, S.; Herve, F.; Libong, D.; Milan, N.; D'Athis, P.; Baud, F. J.; Ricordel, I. Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. J. Chromatogr. B, 2004, 807, 335-342. (Pubitemid 38760001)
130. Drugs.com - Drug information online, Midazolam drug interactions. http://www.drugs.com/drug-interactions/midazolam.html (Accessed October 13, 2010).
131. Drugs.com - Drug information online, Drug interactions between Agenerase and midazolam. http://www.drugs.com/drug-interacti-ons/agenerase-with-midazolam- 199-91-1628-0.html (Accessed October 13, 2010).
132. Hanley, M. J.; Cerundolo, R.; Radwanski, N.; Court, M. H. Grapefruit juice, lyophilized grapefruit juice, and powdered whole grapefruit inhibit cytochrome P450-mediated triazolam hydroxylation by beagle dog liver microsomes. J. Vet. Pharmacol. Ther., 2010, 33(2), 189-195.